Prof Daniel Powell Jr
Dr. Daniel Powell Jr. is an international expert in cancer immunobiology and translational immunotherapy. He is recognized for his extensive studies of the role the T cell response in the control of human cancer, and the application of adoptive lymphocyte immunotherapy, immunomodulation and cancer vaccination in various cancer types. Dr. Powell is an Associate Professor in the Perelman School of Medicine at the University of Pennsylvania with appointments in the Department of Pathology and Laboratory Medicine and the Department of Obstetrics and Gynecology. Dr. Powell maintains a research laboratory that is actively developing novel immunotherapeutic strategies, including experimental cell-based therapeutics, genetically-modified T cell therapy, dendritic cell based cancer vaccination, antibody-based immune checkpoint inhibition and combination immune/chemotherapy for the treatment of a variety of malignancies, with a primary focus on gynecological cancers. Dr. Powell has a strong track record in translational immunotherapy of cancer and serves on various Advisory Boards. He holds several patents in the area of T cell and antibody therapy, with an emphasis on CAR T cell immunotherapy. Dr. Powell previously served as the Deputy Director of PENN’s Cell and Vaccine Production Facility within the Abramson Cancer Center and actively directs the Clinical Tumor Tissue Facility (CTTF), in support of multiple Phase I and II immunotherapy trials. Dr. Powell serves on various grant review committees, including those for the NHLBI’s Production Assistance for Cellular Therapies (PACT). His research excellence has been recognized by multiple awards including the American Society of Gene & Cell Therapy’s Outstanding New Investigator Award, and NIH Exceptional Performance Awards.